Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27314830 | 0.82 | GABRA1 (0.39) | CYP11B1CYP11B2APLNRCYP19A1ALDH1A1 | |
| SCHEMBL13885073 | 0.82 | APLNR (0.35) | APLNR | |
| SCHEMBL27314463 | 0.82 | GABRA1 (0.39) | CYP11B1CYP11B2APLNRCYP19A1ALDH1A1 | |
| SCHEMBL3749196 | 0.82 | CYP11B1 (0.43) | TAS2R14KIF11CYP11B1CYP11B2HDAC4 | |
| SCHEMBL21945058 | 0.80 | CYP11B2 (0.45) | CYP11B1CYP11B2 | |
| SCHEMBL8170002 | 0.76 | GABRA1 (0.54) | KIF11CYP11B1CYP11B2APLNRHDAC4 | |
| SCHEMBL8765679 | 0.76 | APLNR (0.38) | CYP11B1CYP11B2APLNRCYP3A4 | |
| SCHEMBL21051408 | 0.76 | KIF11 (0.59) | KIF11CYP11B1CYP11B2 | |
| SCHEMBL31403052 | 0.76 | KIF11 (0.59) | KIF11CYP11B1CYP11B2ALDH1A1PTGS1 | |
| SCHEMBL21744244 | 0.75 | CYP11B2 (0.56) | KIF11CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | disclosed |
| US-12622917-B2 | High-activity Wnt pathway inhibitor compound | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| EP-4466266-B1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | TRANSNEURAL THERAPEUTICS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12486268-B2 | Fused heterocycles as 5-HT2A receptor agonists | Transneural Therapeutics, Inc. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4647429-A1 | PYRIDAZINONE HETEROCYCLIC COMPOUND MYOSIN II INHIBITOR AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2025-11-12 | — | — | EP | disclosed |
| US-12459944-B2 | Fused heterocycles as 5-HT2A receptor agonists | Transneural Therapeutics, Inc. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | BAUSCH + LOMB IRELAND LIMITED (IE) | 2025-10-07 | — | — | US | disclosed |
| US-20250262205-A1 | DUAL MAGL AND FAAH INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-12384790-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| WO-2000071520-A2 | ARYL SUBSTITUTED ALKYLAMINES CAPABLE OF ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| EP-1047690-A1 | HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | Abbott Laboratories (US) | 2000-11-02 | — | — | EP | disclosed |
| WO-2000062767-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION | TARGACEPT, INC. (US) | 2000-10-26 | — | — | WO | disclosed |
| WO-1999051216-A2 | 3-PYRIDYLOXYALKYLAMINE OR ARYLOXYALKYLAMINE DERIVATIVES AS CHOLINERGIC AGONISTS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-10-14 | — | — | WO | disclosed |
| US-5948793-A | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release | ABBOTT LABORATORIES (US) | 1999-09-07 | — | — | US | disclosed |
| WO-1999032480-A1 | HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 1999-07-01 | — | — | WO | disclosed |
| US-5914328-A | CONTROL DOPAMINE RELEASE, ACTIVATE CHOLINERGIC CHANNELS | ABBOTT LABORATORIES (US) | 1999-06-22 | — | — | US | disclosed |
| EP-0846114-A1 | 3-PYRIDYLOXYALKYL HETEROCYCLIC ETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | Abbott Laboratories (US) | 1998-06-10 | — | — | EP | disclosed |
| EP-0778267-A1 | SULFONAMIDE DERIVATIVES AND INSECTICIDE, MITICIDE AND NEMATICIDE CONTAINING THE SAME | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996040682-A1 | 3-PYRIDYLOXYALKYL HETEROCYCLIC ETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459944-B2 | Fused heterocycles as 5-HT2A receptor agonists | HTR2A, HTR2C, HTR5A | TAS2R14 950/4885KIF11 4121/4885CYP11B1 801/4885 |
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | TRPV1, TRPV3, TRPV2 | TAS2R14 479/4885KIF11 4205/4885CYP11B1 268/4885 |
| US-20260137680-A1 | NOVEL COMPOUNDS | CCR1, CCR4, CCR3 | TAS2R14 3497/4885KIF11 4152/4885CYP11B1 48/4885 |
| US-12622917-B2 | High-activity Wnt pathway inhibitor compound | WNT1, WNT3, WNT3A | TAS2R14 3409/4885KIF11 4553/4885CYP11B1 545/4885 |
| US-20250262205-A1 | DUAL MAGL AND FAAH INHIBITORS | FAAH, FAAH2, MAG | TAS2R14 3390/4885KIF11 1776/4885CYP11B1 4378/4885 |
| US-12486268-B2 | Fused heterocycles as 5-HT2A receptor agonists | HTR2A, HTR2C, HTR5A | TAS2R14 950/4885KIF11 4121/4885CYP11B1 801/4885 |
| US-12384790-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | TAS2R14 4289/4885KIF11 2629/4885CYP11B1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.